Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01041105 · ClinicalTrials.gov registry record

Gastric Bypass After Previous Anti-reflux Surgery

A clinical trial of Gastroesophageal Reflux Disease and Clinically Severe Obesity, sponsored by University of California, San Francisco.

Completed
Registry status
22
Enrollment target
1
Study location

NCT01041105 is a study of Gastroesophageal Reflux Disease and Clinically Severe Obesity that has completed, run by University of California, San Francisco. The registered enrollment target is 22 participants, below the 347-participant average among 24 other Gastroesophageal Reflux Disease trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01041105, a study of Gastroesophageal Reflux Disease and Clinically Severe Obesity, has completed, sponsored by University of California, San Francisco.

COMPLETED
Registry status
22 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to describe the clinical presentation, indications, and operative treatment as well as assess the morbidity, mortality, and overall performance of revisional Roux-en-Y gastric bypass (RYGB) after either failed or functional antireflux surgery "ARS" in obese patients. With such information, we hope to determine which features might assist us in advancing our knowledge about Gastro-Esophageal Reflux Disease "GERD", the best option for primary ARS, and mechanisms of failure in the obese population as well as in identifying predictors of outcome after revisional surgery in this population.

Study Locations (1)

California

  • UCSF Fresno Center for Medical Education and Research - Fresno

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2008-12
Est. Completion 2009-12

What the Registry Record Tells You About NCT01041105

The ClinicalTrials.gov registry entry for NCT01041105 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 347-participant average among 24 other Gastroesophageal Reflux Disease trials with a reported enrollment target (94% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Gastroesophageal Reflux Disease appearing as the primary indexed condition, and to 0 interventions.

NCT01041105 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01041105 about?

NCT01041105 is a clinical study titled "Gastric Bypass After Previous Anti-reflux Surgery". The goal of this study is to describe the clinical presentation, indications, and operative treatment as well as assess the morbidity, mortality, and overall performance of revisional Roux-en-Y gastric bypass (RYGB) after either failed or functional antireflux surgery "ARS" in obese patients. With s...

What is the current status of trial NCT01041105?

This trial is currently completed. The enrollment target is 22 participants. The study started on 2008-12. Estimated completion is 2009-12.

What conditions does trial NCT01041105 study?

This clinical trial studies the following conditions: Gastroesophageal Reflux Disease, Clinically Severe Obesity.

Who is sponsoring clinical trial NCT01041105?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01041105 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastroesophageal Reflux Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.